Summary of adverse events.

<p>Summary of adverse events.</p

DBS-related neurological and psychiatric adverse events.

<p>DBS-related neurological and psychiatric adverse events.</p

CTC grade of SAE vs relatedness to DBS therapy.

<p>CTC grade of SAE vs relatedness to DBS therapy.</p

Sum of AEs defined by same severity, reversibility, and attribution to DBS therapy.

<p>Green, reversible; orange, non reversible; grey, unknown. The actual number of AEs is presented. The dotted area indicates AEs that were <i>severe</i> or worse and at least <i>possibly</i> related to DBS therapy and, thus, regarded the most critical. N.B. The number of affected patients may be less than the number indicated because individual patients may have suffered from more than one AE of respective groups (e.g. impairment of gait and speech rated as <i>mild</i>, <i>probably</i> related and <i>non-reversible</i>).</p

Reporting of adverse events in prospective multicentric DBS studies for movement disorders.

<p>Reporting of adverse events in prospective multicentric DBS studies for movement disorders.</p

(Supplement) DBS-related and -unrelated neurological and psychiatric adverse events.

<p>(Supplement) DBS-related and -unrelated neurological and psychiatric adverse events.</p